Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
PipCast®
PTE
Trade Marks
Webinars
Pearce IP BioBlast w/e 8 April 2022

Pearce IP BioBlast w/e 8 April 2022

31 March 22 | Fresenius Kabi announced that it has bought a majority stake (55%) in mAbxience, a company specialising in biosimilars, for an upfront EUR 495 million plus milestone payments, and Ivenix, which has a leading infusion therapy platform, for an upfront US$...
Pearce IP BioBlast w/e 8 April 2022

Pearce IP BioBlast w/e 1 April 2022

28 Mar 22 | Aurobindo announced that it will acquire certain business assets from Veritaz (the supplier of branded generic formulations and other health care products) for Rs 171 crore on a debt free basis.  The acquisition will support Aurobindo’s plans to...
Pearce IP BioBlast w/e 8 April 2022

Pearce IP BioBlast w/e 25 March 2022

19 Mar 22 | US | Amgen and Pfizer settled their pegfilgrastim (Neulasta®) dispute Amgen Inc v Hospira Inc (D. Del., No. 20-201) which has been on foot since February 2020.  No further details about the settlement agreement have been published to date.   21 Mar 22 |...
Pearce IP BioBlast w/e 8 April 2022

Pearce IP BioBlast w/e 18 March 2022

14 Mar 22 | OcyonBio announced that it has entered into a manufacturing and operations agreement with Biosimilar Solutions Inc. to create a contract biosimilars development/manufacturing organisation (including process development, plasmid, vectors, cell banks,...
Pearce IP BioBlast w/e 8 April 2022

Pearce IP BioBlast w/e 11 March 2022

03 Mar 22 | US | FDA announced a new funding opportunity for the BsUFA III Regulatory Science Program to support research projects that “enhance biosimilar and interchangeable biological product development and regulatory science”. 07 Mar 22 | Merck published interim...